Abstract
Scope of Report
The scope of this report will primarily concentrate on the R&D competitive
landscape for Multiple Sclerosis (MS) from a clinical perspective.
This methodological approach is intended to provide insight into the strategic
opportunities and challenges, as well as the clinical hurdles facing MS drug
developers.
Specifically, the focus of our analysis is on the clincial trial design and
data results for compounds in phase II or beyond that have the potential to
alter the market dynamics in MS over the next 3-7 years.
View Cart
